APO RESEARCH · REPORT
Fibrinogen
Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen Concentrate is used as a medicine for blood disease. Fibrinogen concentrate is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer’s products are justly used in local region or countries.
Product & engineering
Understand the product.
Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen Concentrate is used as a medicine for blood disease. Fibrinogen concentrate is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer’s products are justly used in local region or countries.
Selected research
Market Structure
Global Fibrinogen Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen Concentrate is used as a medicine for blood disease. Fibrinogen concentrate is a preparation of coagulation factors prepared from pooled plasma. Currently, only RiaSTAP (CSL Behring) is licensed in a number of countries for multiple indications including treating acute bleeding episodes with Hypofibrinogenemia. Other manufacturer’s products are justly used in local region or countries.
Global core fibrinogen manufacturers include CSL Behring, LFB Group and Shanghai RAAS Blood Products etc. The top 1 companies hold a share about 52%. North America is the largest market, with a share about 31%, followed by Europe and Asia Pacific with the share about 28% and 26%.
This report provides an overview of the global Fibrinogen market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
Read the full market overview
The study covers key producers of Fibrinogen and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Fibrinogen sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Fibrinogen market size, projected growth trends, production technologies, key applications, and end-use industries.
Fibrinogen Segment by Company
CSL Behring
LFB Group
Shanghai RAAS Blood Products
Jiangxi Boya Bio-Pharmaceutical
Hualan Biological Engineering
Harbin Pacific Biopharmaceutical
GREEN CROSS
Shanghai XinXing Medical
Taibang Biologic
Octapharma
Fibrinogen Segment by Type
Human Fibrinogen
Animal Fibrinogen
Fibrinogen Segment by Application
Congenital Fibrinogen Deficiency
Surgical Procedures
Others
Fibrinogen Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fibrinogen market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Fibrinogen and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fibrinogen.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Fibrinogen market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fibrinogen manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Fibrinogen in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Fibrinogen in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Human Fibrinogen
- Animal Fibrinogen
Applications
- Congenital Fibrinogen Deficiency
- Surgical Procedures
- Others
Companies covered
- CSL Behring
- LFB Group
- Shanghai RAAS Blood Products
- Jiangxi Boya Bio-Pharmaceutical
- Hualan Biological Engineering
- Harbin Pacific Biopharmaceutical
- GREEN CROSS
- Shanghai XinXing Medical
- Taibang Biologic
- Octapharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Fibrinogen Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Fibrinogen Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Fibrinogen Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Fibrinogen Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Fibrinogen Market Dynamics
- 2.1 Fibrinogen Industry Trends
- 2.2 Fibrinogen Industry Drivers
- 2.3 Fibrinogen Industry Opportunities and Challenges
- 2.4 Fibrinogen Industry Restraints
3 Fibrinogen Market by Manufacturers
- 3.1 Global Fibrinogen Revenue by Manufacturers (2021-2026)
- 3.2 Global Fibrinogen Sales by Manufacturers (2021-2026)
- 3.3 Global Fibrinogen Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Fibrinogen Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Fibrinogen Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Fibrinogen Manufacturers, Product Type & Application
- 3.7 Global Fibrinogen Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Fibrinogen Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Fibrinogen Players Market Share by Revenue in 2025
- 3.8.3 2025 Fibrinogen Tier 1, Tier 2, and Tier 3
4 Fibrinogen Market by Type
- 4.1 Fibrinogen Type Introduction
- 4.1.1 Human Fibrinogen
- 4.1.2 Animal Fibrinogen
- 4.2 Global Fibrinogen Sales by Type
- 4.2.1 Global Fibrinogen Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Fibrinogen Sales by Type (2021-2032)
- 4.2.3 Global Fibrinogen Sales Market Share by Type (2021-2032)
- 4.3 Global Fibrinogen Revenue by Type
- 4.3.1 Global Fibrinogen Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Fibrinogen Revenue by Type (2021-2032)
- 4.3.3 Global Fibrinogen Revenue Market Share by Type (2021-2032)
5 Fibrinogen Market by Application
- 5.1 Fibrinogen Application Introduction
- 5.1.1 Congenital Fibrinogen Deficiency
- 5.1.2 Surgical Procedures
- 5.1.3 Others
- 5.2 Global Fibrinogen Sales by Application
- 5.2.1 Global Fibrinogen Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Fibrinogen Sales by Application (2021-2032)
- 5.2.3 Global Fibrinogen Sales Market Share by Application (2021-2032)
- 5.3 Global Fibrinogen Revenue by Application
- 5.3.1 Global Fibrinogen Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Fibrinogen Revenue by Application (2021-2032)
- 5.3.3 Global Fibrinogen Revenue Market Share by Application (2021-2032)
6 Global Fibrinogen Sales by Region
- 6.1 Global Fibrinogen Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Fibrinogen Sales by Region (2021-2032)
- 6.2.1 Global Fibrinogen Sales by Region (2021-2026)
- 6.2.2 Global Fibrinogen Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Fibrinogen Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Fibrinogen Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Fibrinogen Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Fibrinogen Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Fibrinogen Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Fibrinogen Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Fibrinogen Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Fibrinogen Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Fibrinogen Revenue by Region
- 7.1 Global Fibrinogen Revenue by Region
- 7.1.1 Global Fibrinogen Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Fibrinogen Revenue by Region (2021-2026)
- 7.1.3 Global Fibrinogen Revenue by Region (2027-2032)
- 7.1.4 Global Fibrinogen Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Fibrinogen Revenue (2021-2032)
- 7.2.2 North America Fibrinogen Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Fibrinogen Revenue (2021-2032)
- 7.3.2 Europe Fibrinogen Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Fibrinogen Revenue (2021-2032)
- 7.4.2 Asia-Pacific Fibrinogen Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Fibrinogen Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Fibrinogen Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 CSL Behring
- 8.1.1 CSL Behring Company Information
- 8.1.2 CSL Behring Business Overview
- 8.1.3 CSL Behring Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 CSL Behring Fibrinogen Product Portfolio
- 8.1.5 CSL Behring Recent Developments
- 8.2 LFB Group
- 8.2.1 LFB Group Company Information
- 8.2.2 LFB Group Business Overview
- 8.2.3 LFB Group Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 LFB Group Fibrinogen Product Portfolio
- 8.2.5 LFB Group Recent Developments
- 8.3 Shanghai RAAS Blood Products
- 8.3.1 Shanghai RAAS Blood Products Company Information
- 8.3.2 Shanghai RAAS Blood Products Business Overview
- 8.3.3 Shanghai RAAS Blood Products Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Shanghai RAAS Blood Products Fibrinogen Product Portfolio
- 8.3.5 Shanghai RAAS Blood Products Recent Developments
- 8.4 Jiangxi Boya Bio-Pharmaceutical
- 8.4.1 Jiangxi Boya Bio-Pharmaceutical Company Information
- 8.4.2 Jiangxi Boya Bio-Pharmaceutical Business Overview
- 8.4.3 Jiangxi Boya Bio-Pharmaceutical Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Jiangxi Boya Bio-Pharmaceutical Fibrinogen Product Portfolio
- 8.4.5 Jiangxi Boya Bio-Pharmaceutical Recent Developments
- 8.5 Hualan Biological Engineering
- 8.5.1 Hualan Biological Engineering Company Information
- 8.5.2 Hualan Biological Engineering Business Overview
- 8.5.3 Hualan Biological Engineering Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Hualan Biological Engineering Fibrinogen Product Portfolio
- 8.5.5 Hualan Biological Engineering Recent Developments
- 8.6 Harbin Pacific Biopharmaceutical
- 8.6.1 Harbin Pacific Biopharmaceutical Company Information
- 8.6.2 Harbin Pacific Biopharmaceutical Business Overview
- 8.6.3 Harbin Pacific Biopharmaceutical Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Harbin Pacific Biopharmaceutical Fibrinogen Product Portfolio
- 8.6.5 Harbin Pacific Biopharmaceutical Recent Developments
- 8.7 GREEN CROSS
- 8.7.1 GREEN CROSS Company Information
- 8.7.2 GREEN CROSS Business Overview
- 8.7.3 GREEN CROSS Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 GREEN CROSS Fibrinogen Product Portfolio
- 8.7.5 GREEN CROSS Recent Developments
- 8.8 Shanghai XinXing Medical
- 8.8.1 Shanghai XinXing Medical Company Information
- 8.8.2 Shanghai XinXing Medical Business Overview
- 8.8.3 Shanghai XinXing Medical Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Shanghai XinXing Medical Fibrinogen Product Portfolio
- 8.8.5 Shanghai XinXing Medical Recent Developments
- 8.9 Taibang Biologic
- 8.9.1 Taibang Biologic Company Information
- 8.9.2 Taibang Biologic Business Overview
- 8.9.3 Taibang Biologic Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Taibang Biologic Fibrinogen Product Portfolio
- 8.9.5 Taibang Biologic Recent Developments
- 8.10 Octapharma
- 8.10.1 Octapharma Company Information
- 8.10.2 Octapharma Business Overview
- 8.10.3 Octapharma Fibrinogen Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Octapharma Fibrinogen Product Portfolio
- 8.10.5 Octapharma Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Fibrinogen Value Chain Analysis
- 9.1.1 Fibrinogen Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Fibrinogen Production Mode & Process
- 9.2 Fibrinogen Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Fibrinogen Distributors
- 9.2.3 Fibrinogen Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst